

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER

SSL0065

U. S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/509695INTERNATIONAL APPLICATION NO.
PCT/FR03/01027INTERNATIONAL FILING DATE
2 April 2003PRIORITY DATE CLAIMED
3 April 2002TITLE OF INVENTION: 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B] INDOLE-1-ACETAMIDE
DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS

APPLICANT(S) FOR DO/EO/US: FROISSANT, Jacques, MARABOT, Benoît, MARGUET, Frank and PUECH, Frédéric

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1)).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application.
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An executed oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
Citation of References
Information Disclosure Statement by Applicant (Form PTO-1449)

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <div style="font-size: 24pt; font-weight: bold;">10/509695</div>		INTERNATIONAL APPLICATION NO. <div style="text-align: center; font-weight: bold;">PCT/FR03/01027</div>		ATTORNEY'S DOCKET NUMBER <div style="text-align: center; font-weight: bold;">SSL0065</div>	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and international Search Report not prepared by the EPO or JPO \$1080.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$920.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .. \$770.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$730.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$100.000 <div style="text-align: right; font-weight: bold;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				CALCULATIONS PTO USE ONLY <div style="border: 1px solid black; height: 100px; width: 100%;"></div>	
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<div style="border: 1px solid black; height: 20px; width: 100%;"></div>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	55 - 20	35	x \$18.00	\$ 700.00	
Independent claims	6 - 3 =	3	x \$86.00	\$ 258.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$290.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$1,878.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				<div style="border: 1px solid black; height: 20px; width: 100%;"></div>	
SUBTOTAL =				\$1,878.00	
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				<div style="border: 1px solid black; height: 20px; width: 100%;"></div>	
TOTAL NATIONAL FEE =				\$1,878.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				<div style="border: 1px solid black; height: 20px; width: 100%;"></div>	
TOTAL FEES ENCLOSED =				\$1,878.00	
				Amount to be refunded:	\$
				Charged	\$1,878.00

a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 19-0091 in the amount of \$1,878.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0091. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Patent Department

Sanofi-Synthelabo Inc.

9 Great Valley Parkway

P.O. Box 3026

Malvern, PA 19355

Facsimile: (610) 889-8799

27546

PATENT TRADEMARK OFFICE

SIGNATURE
DATE

Michael D. Alexander

NAME

36,080

REGISTRATION NUMBER

(610) 889-8802

TELEPHONE NUMBER

10/509695

DT09 REC'D PCT/PTO 30 SEP 2004

Application of: FROISSANT, Jacques, MARABOT, Benoît,
MARGUET, Frank and PUECH, Frédéric

Docket No.: SSL0065

Filing Under 35 U.S.C. § 371

Filed As a U.S. National Phase Application of
International Application No. PCT/FR03/001027
Filed 2 April 2003

FOR: 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-
PYRIDAZINO[4,5-B] INDOLE-1-ACETAMIDE DERIVATIVES,
THEIR PREPARATION AND THEIR APPLICATION IN
THERAPEUTICS

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label No.: EV 525096431 US

Date of Deposit: September 30, 2004

I hereby certify that this paper is being deposited with the United States
Postal Service "Express Mail Post Office to Addressee" Service on the
date indicated above, and is addressed to: Mail Stop PCT,

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450


Signature